Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹262 Cr.
Stock P/E
6.3
P/B
0.4
Current Price
₹137.7
Book Value
₹ 375
Face Value
10
52W High
₹207
52W Low
₹ 126.8
Dividend Yield
1.45%

Nath Bio-Genes (I) Overview

Business

Nath Bio-Genes (India) Ltd. is an agricultural biotechnology company primarily engaged in the research, development, production, processing, and marketing of hybrid seeds. The company's core business model revolves around developing high-yielding and disease-resistant seed varieties for various crops, selling these seeds to farmers through an extensive distribution network across different states in India. It generates revenue by providing solutions to enhance agricultural productivity and farmer income.

Revenue Mix

The company's revenue is primarily derived from the sale of hybrid seeds. While precise percentage breakdowns can vary and are not always detailed publicly, Nath Bio-Genes typically focuses on a portfolio of key crops including:

Field Crops: Cotton (e.g., Bt cotton hybrids), Maize, Paddy (Rice), Pearl Millet, Sorghum, Sunflower.

Vegetable Crops: Okra, Tomato, Chilli, Brinjal, Cabbage, Cauliflower, Gourds, etc.

The primary revenue drivers are usually cotton and maize seeds, followed by paddy and various vegetable seeds.

Industry

The Indian agriculture industry, particularly the seed sector, is vast, diverse, and highly dependent on climatic conditions and government policies. It is characterized by the coexistence of large multi-national companies, established domestic players, and numerous smaller regional companies. Nath Bio-Genes is positioned as an established Indian seed company with a significant presence in hybrid seeds, particularly in certain regions and specific crops like cotton and maize. It competes with global giants like Bayer (erstwhile Monsanto) and Syngenta, as well as strong domestic players such as Kaveri Seed Company, Nuziveedu Seeds, and JK Agri Genetics. Its positioning relies on its R&D capabilities, regional market penetration, and product portfolio catering to local agricultural needs.

MOAT

Nath Bio-Genes possesses certain competitive advantages, though not necessarily a wide economic moat in a highly competitive industry:

R&D Capabilities: Long-standing focus on developing proprietary hybrid seed varieties through its in-house R&D, leading to specific crop traits like yield improvement and disease resistance.

Distribution Network: An established and wide distribution network across key agricultural states in India, ensuring product reach to farmers.

Farmer Trust: Over decades of operation, the company has built a level of brand recognition and trust among farmers in its target markets due to consistent product performance.

Product Portfolio: A diverse portfolio across field and vegetable crops, reducing over-reliance on a single crop.

Growth Drivers

Increased Adoption of Hybrid Seeds: Continued shift from traditional/local varieties to higher-yielding hybrid seeds by Indian farmers seeking better productivity and income.

Population Growth & Food Security: Rising population and the need for enhanced food production will drive demand for quality seeds.

Product Innovation & Pipeline: Introduction of new, superior hybrid varieties (e.g., drought-tolerant, pest-resistant) through ongoing R&D can drive market share gains.

Market Expansion: Increasing presence in untapped or under-penetrated agricultural regions within India.

Government Focus on Agriculture: Supportive government policies, subsidies, and schemes aimed at boosting agricultural output and farmer welfare can indirectly benefit seed companies.

Risks

Monsoon Dependency: Agricultural output and seed demand are heavily dependent on timely and adequate monsoons. Adverse weather conditions (droughts, floods) can significantly impact sales.

Regulatory Changes: Government policies related to seed pricing (e.g., cap on Bt cotton seed prices), approval processes for new biotech crops, and intellectual property rights can impact profitability and R&D investment.

Intense Competition: The seed market is highly competitive with both large multinational and strong domestic players, leading to pricing pressures and market share battles.

Pest and Disease Outbreaks: Emergence of new pests or diseases can necessitate continuous R&D investment and render existing seed varieties less effective.

Working Capital Management: The seasonal nature of the seed business requires significant working capital management for production, inventory, and receivables.

Genetic Contamination/Quality Issues: Any issues with seed quality or genetic purity can severely damage brand reputation and lead to financial losses.

Management & Ownership

Nath Bio-Genes (India) Ltd. is promoted by the Nath family, with Mr. Satish Nath as the Chairman & Managing Director. The management team comprises experienced professionals in the agriculture and biotechnology sectors. The promoter group typically holds a significant stake in the company, indicating strong alignment of interests. The company is publicly listed, with the remaining shares held by institutional investors, high net worth individuals, and the public.

Outlook

Nath Bio-Genes operates in a fundamental sector critical for India's food security and rural economy. The long-term demand for quality hybrid seeds is expected to remain robust due to population growth and the continuous need for higher agricultural productivity. The company's established R&D capabilities and widespread distribution network position it to capitalize on this trend. However, the business faces significant cyclicality due to weather dependence and regulatory uncertainties, particularly regarding GM crops and seed pricing. Intense competition and the continuous need for R&D investment to stay relevant are ongoing challenges. Success hinges on its ability to consistently develop and market superior seed varieties while effectively managing operational and regulatory risks in a dynamic agricultural landscape.

Nath Bio-Genes (I) Share Price

Live · BSE / NSE · Inception: 2000
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Nath Bio-Genes (I) Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 43 244 32 37 52 284 44 66 52 328
Other Income 0 0 0 0 4 2 2 2 2 2
Total Income 43 244 32 37 56 285 46 68 54 330
Total Expenditure 39 207 27 29 52 254 38 62 47 293
Operating Profit 4 37 5 9 4 31 8 5 7 37
Interest 1 2 3 4 1 3 4 5 5 4
Depreciation 1 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 2 0 3 1 1
Profit Before Tax 2 34 1 4 2 29 3 2 2 33
Provision for Tax 1 0 -0 1 1 1 1 1 3 1
Profit After Tax 2 33 1 3 1 28 3 2 -0 32
Adjustments 1 0 -0 0 1 0 0 -0 0 0
Profit After Adjustments 3 33 1 3 1 28 3 2 -0 32
Adjusted Earnings Per Share 1.4 17.6 0.6 1.4 0.8 14.9 1.4 0.8 -0 17

Nath Bio-Genes (I) Profit & Loss

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 124 138 278 301 333 365 445 490
Other Income 1 1 2 1 1 5 8 8
Total Income 125 138 280 302 333 369 453 498
Total Expenditure 109 118 241 252 283 315 392 440
Operating Profit 16 20 39 50 51 55 60 57
Interest 2 4 11 10 9 11 16 18
Depreciation 5 5 3 3 3 4 4 4
Exceptional Income / Expenses 0 0 -89 0 3 1 6 5
Profit Before Tax 9 12 -63 36 42 41 46 40
Provision for Tax -0 1 4 1 2 2 5 6
Profit After Tax 9 12 -67 35 40 39 42 37
Adjustments 0 0 0 0 0 0 0 0
Profit After Adjustments 9 12 -67 35 40 39 42 37
Adjusted Earnings Per Share 0 0 -35.5 18.4 20.8 20.3 21.9 19.2

Nath Bio-Genes (I) Balance Sheet

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 46 57 542 573 610 644 680
Minority's Interest 0 0 -0 0 0 0 0
Borrowings 1 1 1 0 5 13 17
Other Non-Current Liabilities 1 1 3 3 3 4 5
Total Current Liabilities 72 98 194 216 262 365 395
Total Liabilities 119 157 739 793 880 1026 1097
Fixed Assets 21 38 245 244 249 250 249
Other Non-Current Assets 2 0 27 29 59 86 69
Total Current Assets 96 120 468 520 572 690 779
Total Assets 119 157 739 793 880 1026 1097

Nath Bio-Genes (I) Cash Flow

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 3 29 4 38 77 89
Cash Flow from Operating Activities 0 14 17 38 75 18 -13
Cash Flow from Investing Activities 0 -21 -20 -3 -27 -4 3
Cash Flow from Financing Activities 0 6 -22 -2 -8 -2 -4
Net Cash Inflow / Outflow 0 -1 -25 34 39 11 -13
Closing Cash & Cash Equivalent 0 2 4 38 77 89 76

Nath Bio-Genes (I) Ratios

# Mar 2012 Mar 2013 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 0 0 -35.46 18.43 20.85 20.31 21.91
CEPS(Rs) 8.69 10.16 -33.84 20.01 22.56 22.32 23.99
DPS(Rs) 0 0 2 2 2 2 2
Book NAV/Share(Rs) 0 0 285.16 301.61 320.94 339.08 358.06
Core EBITDA Margin(%) 11.84 14.45 13.37 16.25 15.02 13.72 11.82
EBIT Margin(%) 8.78 11.6 -18.96 15.44 15.26 14.06 14.03
Pre Tax Margin(%) 7.32 8.93 -22.79 12 12.5 11.12 10.4
PAT Margin (%) 7.42 8.53 -24.21 11.62 11.91 10.58 9.35
Cash Profit Margin (%) 11.22 11.8 -23.1 12.62 12.89 11.62 10.24
ROA(%) 7.73 8.5 -15.03 4.57 4.74 4.05 3.92
ROE(%) 20.12 22.76 -22.48 6.28 6.7 6.15 6.28
ROCE(%) 19.09 23.88 -14.84 7.09 7.26 6.9 7.88
Receivable days 36.68 44.32 69.85 110.74 105.14 91.63 71.47
Inventory Days 193.69 189.43 195.06 259.3 240.4 284.23 323.33
Payable days 1576.65 -4219.16 1503.38 744.29 -1457.17 -249 -367.18
PER(x) 0 0 0 7.69 8.33 7.18 5.83
Price/Book(x) 0 0 0.75 0.47 0.54 0.43 0.36
Dividend Yield(%) 0 0 0.94 1.41 1.15 1.37 1.57
EV/Net Sales(x) 0.19 0.24 1.78 1.12 1.09 0.85 0.69
EV/Core EBITDA(x) 1.54 1.6 12.65 6.79 7.18 5.69 5.05
Net Sales Growth(%) 0 11.13 102.15 8.26 10.37 9.71 21.98
EBIT Growth(%) 0 46.76 -430.58 188.13 9.13 1.09 21.71
PAT Growth(%) 0 27.66 -673.7 151.96 13.16 -2.57 7.85
EPS Growth(%) 0 0 -583.1 151.98 13.11 -2.57 7.85
Debt/Equity(x) 0.25 0.33 0.17 0.18 0.18 0.19 0.2
Current Ratio(x) 1.34 1.22 2.41 2.4 2.18 1.89 1.97
Quick Ratio(x) 0.42 0.43 1.27 1.44 1.3 0.96 0.83
Interest Cover(x) 6.02 4.35 -4.96 4.49 5.52 4.78 3.86
Total Debt/Mcap(x) 0 0 0.23 0.39 0.33 0.44 0.57

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +22% +14% +26% —
Operating Profit CAGR +9% +6% +25% —
PAT CAGR +8% +6% +28% —
Share Price CAGR -18% -13% -16% +2%
ROE Average +6% +6% +1% +7%
ROCE Average +8% +7% +3% +8%

Nath Bio-Genes (I) Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 45.6 %
FII 0.26 %
DII (MF + Insurance) 0.01 %
Public (retail) 54.13 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 45.645.645.645.645.645.645.645.645.645.6
FII 0.270.210.180.190.210.410.320.310.220.26
DII 4.374.374.374.373.952.250.760.010.010.01
Public 49.7649.8249.8549.8450.2551.7453.3254.0854.1754.13
Others 0000000000
Total 100100100100100100100100100100

Nath Bio-Genes (I) Peer Comparison

Agriculture Edit Columns

Nath Bio-Genes (I) Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Nath Bio-Genes (I) Pros & Cons

Pros

  • Stock is trading at 0.4 times its book value
  • Company has delivered good profit growth of 28% CAGR over last 5 years
  • Debtor days have improved from -249 to -367.18days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 45.6%.
  • Company has a low return on equity of 6% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp